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Surveillance in Africa’s meningitis belt: time for new targets?
Current WHO guidelines for the detection of 
meningococcal disease outbreaks in the meningitis belt 
in Africa deﬁ ne suspected meningitis as sudden onset 
of fever (>38·5°C rectal or 38·0°C axillary) and one of 
the following signs: neck stiﬀ ness, ﬂ accid neck (infants), 
bulging fontanelle (infants), convulsion, or other 
meningeal signs.1 Although these signs are classic for 
meningitis, they were used when the predominant causal 
pathogen of these outbreaks was Neisseria meningitidis 
serogroup A (NmA). After widespread implementation of 
vaccination with MenAfriVac (NmA conjugate vaccine), 
the number of outbreaks caused by this strain has 
decreased with a relative or absolute increase in disease 
caused by other Neisseria strains and other bacterial 
species. The change in epidemiology is likely to aﬀ ect 
clinical presentation, and review of clinical management 
guidelines for the subregion is urgently needed. Because 
conﬁ rmation of the cause of most cases during these 
outbreaks is diﬃ  cult due to resource constraints, lessons 
can be learnt from disease caused by similar strains in 
locations where resources for evaluation and monitoring 
are better. 
In a report from the UK,2 an outbreak of 
W135 N meningitidis was observed between July, 2015, 
and January, 2016, in 15 adolescents who did not 
have any direct epidemiological, temporal, or spatial 
links. All these patients presented predominantly with 
gastrointestinal symptoms. A clinical diagnosis of 
meningitis was conﬁ rmed from cerebrospinal ﬂ uid in 
only one of the 15 patients. Septicaemia was reported 
in ten of 15 patients, two patients had septic arthritis, 
two had pneumonia, and one presented with sore 
throat, fatigue, and lethargy. The outcome of illness was 
fatal in six of the 15 patients. All culture isolates were 
subsequently conﬁ rmed as W.2A (a surrogate marker 
for the hypervirulent sequence type 11 clonal complex), 
apart from one patient who had pneumonia (serotyped 
as NT/NT/NT). Laboratory-conﬁ rmed group W invasive 
meningococcal disease has increased in the UK from 
19 cases in 2008–09 to 176 cases in 2014–15.3 The 
unusual presentation of invasive meningococcal disease 
caused by group W has also been reported in Chile, with 
eight fatalities in 14 cases.4
Comparative data on the clinical presentation 
and outcome in NmC and NmA are scarce. In a brief 
report5 from northern Nigeria in 1977, 114 patients 
with meningococcal infection were studied, of whom 
72 patients had NmC infection and 42 patients had 
NmA infection. All patients who had bacteraemia had 
disease caused by NmC infection, and nine of these 
14 patients died. Clinical and laboratory ﬁ ndings were 
similar in patients with meningitis due to NmA and 
NmC, but arthritis and cutaneous vasculitis were more 
common in patients with NmC. The overall mortality 
rate was 22% in patients infected with NmC, and 12% in 
patients infected with NmA. Notably, the investigators 
reported similar mortality rates for both diseases when 
the patients who had bacteraemia were excluded 
from the analysis. The excess mortality rate in patients 
infected with NmC would have been missed in the 
absence of surveillance for bacteraemia.
Reports of non-serogroup-A meningococcal disease 
in the meningitis belt are increasing, consisting of 
outbreaks caused by NmW, NmC, and serogroup 1 
strain of Streptococcus pneumoniae in northern Ghana.6 
This trend clearly shows the need to provide more 
comprehensive surveillance platforms for invasive 
meningococcal disease in the meningitis belt, where 
diagnosis of disease has relied on the recognition of 
meningeal symptoms and assessment of cerebrospinal 
ﬂ uid alone without consideration for patients with 
invasive meningococcal disease, who are at high risk 
of a fatal outcome. Blood cultures are not routinely 
done and no intensive care units exist. This change in 
epidemiology of disease warrants an urgent review 
of the surveillance and management approaches 
in place for these outbreaks. First, the clinical case 
deﬁ nition should be broadened to include patients with 
septicaemia at clinical presentation without meningeal 
signs. Second, provision for integrating bacteraemia 
surveillance should be included in the laboratory 
investigation, either by blood culture or another suitable 
method for the detection and identiﬁ cation of bacteria 
from the blood stream. Third, the recommended 
threshold for outbreak alerts and epidemics should 
be revised because outbreaks caused by non-A 
meningococcal meningitis serogroups have less clear 
patterns of outbreak, and analysis of the epidemic risk 
at the subdistrict level could be poorly sensitive. Finally, 
improved understanding of the dynamics of these 
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outbreaks will be best accomplished by establishing 
local and regional microbiological diagnostic, year-
round surveillance to track disease incidence and provide 
causal data that will guide preventive strategies, in the 
short term and long term.
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